

US009274102B2

(12) United States Patent

Namba et al.

(10) Patent No.: US 9,274,102 B2 (45) Date of Patent: Mar. 1, 2016

(54) METHOD OF SCREENING FOR AN INHIBITOR OF ODOR CAUSE BY FURANEOL

- (71) Applicant: Kao Corporation, Chuo-ku, Tokyo (JP)
- (72) Inventors: Aya Namba, Katsushika-ku (JP); Naoko

Saito, Utsunomiya (JP); Michiaki Inoue, Cincinnati, OH (US); Tsuyoshi

Toyabe, Funabashi (JP)

- (73) Assignee: Kao Corporation, Tokyo (JP)
- (*) Notice: Subject to any disclaimer, the term of this

patent is extended or adjusted under 35

U.S.C. 154(b) by 0 days.

- (21) Appl. No.: 14/519,958
- (22) Filed: Oct. 21, 2014

(65) Prior Publication Data

US 2015/0111229 A1 Apr. 23, 2015

(30) Foreign Application Priority Data

Oct. 22, 2013 (JP) 2013-219336

(51) Int. Cl. *G01N 33/50*

(2006.01)

(52) U.S. Cl.

CPC *G01N 33/5044* (2013.01)

(58) Field of Classification Search

CPC A61K 39/39533; G01N 33/50; G01N 2500/04; G01N 2500/10

See application file for complete search history.

(56) References Cited

U.S. PATENT DOCUMENTS

2013/0210022	A 1	8/2013	Kato et al.
2013/0210775	A1	8/2013	Kato et al.
2014/0186864	A1	7/2014	Kato et al.
2015/0110669	A1	4/2015	Namba et al.
2015/0110731	A1	4/2015	Namba et al.

FOREIGN PATENT DOCUMENTS

JP	2012-250958 A	12/2012
JP	2015-081237 A	4/2015
JP	2015-202075 A	11/2015
JP	2015-202076 A	11/2015
JP	2015-202077 A	11/2015
WO	WO 2009/078360 A1	6/2009
WO	WO 2012/169644 A1	12/2012

OTHER PUBLICATIONS

Indo, M., Synthetic Flavor and Fragrance, Enlarged and Revised Edition, 2005, The Chemical Daily Co., Ltd., Tokyo, Japan, pp. 348-349.

Cutzach, I et al., "Identification of volatile compounds with a 'toasty' aroma in heated oak used in barrelmaking," J Agric Food Chem, Jun. 1997, 45: 2217-2224, Am. Chem Soc, Washington, DC.

Karagül-Yüceer, Y et al., "Aroma characterization of fresh and stored-nonfat dry milk," Chapter 8 in Freshness and Shelf Life of Foods, ACS Symposium Series vol. 836, Keith R. Cadwallader et al., eds., Oct. 2002, pp. 108-123, Am. Chem. Soc, Washington, DC.

Botelho, G et al., "Characterisation of free and glycosidically bound odourant compounds of Aragonez clonal musts by GC-O," Anal Chim Acta, Jan. 2010; 657(2): 198-203, Elsevier, Amsterdam, Netherlands.

Excerpted file history of U.S. Appl. No. 14/519,962, filed Oct. 21, 2014: Non-final office action mailed Nov. 25, 2015 by the United States Patent and Trademark Office, Alexandria, VA.

Primary Examiner — Robert Landsman (74) Attorney, Agent, or Firm — Sterne, Kessler, Goldstein & Fox P.L.L.C.

(57) ABSTRACT

It is intended to identify a substance inhibiting an odor caused by 2,5-dimethyl-4-hydroxy-3(2H)-furanone. The present invention provides a method for searching for an inhibitor of an odor caused by 2,5-dimethyl-4-hydroxy-3(2H)-furanone, comprising: adding a test substance and 2,5-dimethyl-4-hydroxy-3(2H)-furanone to an olfactory receptor OR5K1 or a polypeptide having at least 80% amino acid sequence identity thereto; measuring the response of the olfactory receptor or the polypeptide to 2,5-dimethyl-4-hydroxy-3(2H)-furanone; and identifying a test substance inhibiting the response of the olfactory receptor or the polypeptide, on the basis of the measured response.

11 Claims, 2 Drawing Sheets

Fig. 1




Fig. 2





Fig. 3



METHOD OF SCREENING FOR AN INHIBITOR OF ODOR CAUSE BY **FURANEOL**

REFERENCE TO SEQUENCE LISTING SUBMITTED ELECTRONICALLY

The content of the electronically submitted substitute sequence listing, file name 1030000 SequenceListing ST25.txt, size 13,719 bytes; and 10 date of creation Oct. 10, 2014, filed herewith, is incorporated herein by reference in its entirety.

FIELD OF THE INVENTION

The present invention relates to a method for searching for an inhibitor of an odor caused by Furaneol.

BACKGROUND OF THE INVENTION

A large number of malodorous molecules differing in polarity or molecular weight are found in our living environments. Various deodorization methods have been developed so far in order to deodorize these diverse malodorous molecules. In general, such deodorization methods are broadly 25 classified into biological methods, chemical methods, physical methods, and sensory methods. Among the malodorous molecules, highly polar short-chain fatty acids or amines can be deodorized by the chemical method, i.e., neutralization reaction. Sulfur compounds such as thiol can be deodorized 30 by the physical method, i.e., adsorption treatment. Still, there remain a large number of malodorous molecules which cannot be dealt with by the conventional deodorization methods. Also, the deodorization method based on adsorption treatment has a problem that it tends to cause the re-emission of a 35 bad smell. In addition, these conventional methods may mask even odors other than the bad smell of interest. Thus, a deodorization method which can overcome these problems has been demanded.

Another known method involves deodorizing a bad smell 40 by rendering a different odor more strongly perceivable using a fragrance. In this method, however, the odor of the fragrance may cause discomfort. In addition, an odorous substance which exhibits an effective deodorizing effect on the malodorous substance of interest must be searched for in order to 45 mask the bad smell by a different odor of a perfume, a fragrance, or the like. Heretofore, sensory tests by experts have been conducted for the evaluation of odors. Such sensory tests, however, has problems such as the need of fostering experts capable of evaluating odors and low throughputs. 50 Thus, the previous search for an odorous substance which exhibits a deodorizing effect has not been easy to achieve.

In mammals such as humans, the sense of smell works by the mechanism where odor molecules bind to olfactory receptors on olfactory nerve cells present in the olfactory epithe- 55 [Non Patent Document 4] Anal Chim Acta., 2010, 657 (2): lium located in the upper region of the nasal cavity to transmit the responses of the receptors thereto to the central nervous system. In humans, approximately 400 olfactory receptors have been reported, and genes encoding these receptors account for approximately 3% of all human genes. In general, 60 a set of olfactory receptors is associated with a set of odor molecules. This means that individual olfactory receptors can respond to a plurality of structurally similar odor molecules with different affinities, while individual odor molecules can be recognized by a plurality of olfactory receptors. According 65 to another report, an odor molecule activating a certain olfactory receptor functions as an antagonist inhibiting the activa-

2

tion of a different olfactory receptor. These combined responses of a set of olfactory receptors render individual odors perceivable.

Accordingly, when a certain odor molecule coexists with a different odor molecule, the different odor molecule may inhibit the response of a receptor corresponding to the certain odor molecule, resulting in the final perception of a different odor. Such a mechanism is called the antagonism of an olfactory receptor. The alteration of an odor caused by this receptor antagonism is a preferred deodorization approach because this approach, unlike the deodorization methods which involve adding another odor of, for example, a perfume, and fragrance can specifically cancel the perception of a bad smell and does not cause discomfort derived from such a fragrance.

Skin tanning agents (also called self-tanning agents or sunless tanning agents) are skin cosmetics which colors the skin. Mainly, dihydroxyacetone (DHA) is used alone or in combination with erythrulose or the like as an ingredient which causes the skin color to turn brown. Such an ingredient reacts with the upper layer of the skin to color the skin brown. Although this coloring is believed to proceed through browning reaction, the details of a mechanism underlying this reaction have hardly been elucidated. The browning reaction is also called Maillard reaction in the field of food chemistry. This term refers to the reaction through which a nitrogencontaining compound such as an amino acid or a protein is polymerized with a reduced sugar to form a brown polymer called melanoidin. The Maillard reaction is involved in food coloring or aroma component formation caused by the heating, etc. of foods.

2,5-Dimethyl-4-hydroxy-3(2H)-furanone (Furaneol) is a substance known to have an odor expressed as a "strong fruity caramel aroma", a "burnt caramel aroma", "burnt sugar", a "curry-like flavor", a "cotton candy smell", etc. (Non-Patent Documents 1 to 4). Patent Document 1 describes a beer-tasted beverage having a taste and flavor or a fragrant smell enhanced by the formation of maltol and Furaneol in a fermentation undiluted solution.

CITATION LIST

Patent Document

[Patent Document 1] WO 2009/078360

Non-Patent Document

[Non-Patent Document 1] Gosei Koryo—Kagaku To Shohin Chishiki—(Synthetic Flavor and Fragrance—Chemistry and Product Knowledge-in English), 2005, The Chemical Daily Co., Ltd.

[Non-Patent Document 2] J. Agric. Food Chem., 1997, 45 (6): 2217-2224

[Non-Patent Document 3] ACS Symp Ser., 2002, 836: 108-

198-203

SUMMARY OF INVENTION

The present invention provides:

a method for searching for an inhibitor of an odor caused by 2,5-dimethyl-4-hydroxy-3(2H)-furanone (Furaneol), comprising:

adding a test substance and 2,5-dimethyl-4-hydroxy-3 (2H)-furanone (Furaneol) to an olfactory receptor OR5K1 or a polypeptide having at least 80% amino acid sequence identity thereto;

measuring the response of the olfactory receptor or the polypeptide to 2,5-dimethyl-4-hydroxy-3(2H)-furanone (Furaneol); and

identifying a test substance inhibiting the response of the olfactory receptor or the polypeptide, on the basis of the measured response.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the responses of olfactory receptors to Furaneol. The abscissa represents individual olfactory receptors. The ordinate represents response intensity.

FIG. 2 shows the response of an olfactory receptor OR5K1 to varying concentrations of Furaneol. n=3, error bar=±SE.

FIG. 3 shows results of sensory evaluation on the inhibitory effects of various compounds on the odor of Furaneol. n=3, error bar=±SE.

DETAILED DESCRIPTION OF THE INVENTION

The term "masking" in relation to odors as used herein refers to a general approach for canceling or weakening the perception of the odor of interest. The "masking" may include chemical approaches, physical approaches, biological approaches, and sensory approaches. Examples of the masking include: an arbitrary approach for removing an odor molecule causative of the odor of interest from the environment (e.g., adsorption and chemical decomposition of the odor molecule); an approach for preventing the odor of interest from being released to the environment (e.g., containment); and a method which involves adding a different odor of a flavor, a fragrance, or the like to reduce the perception of odor of interest

The term "masking based on olfactory receptor antago- 35 nism" as used herein refers to one form of the above-mentioned "masking" in a broad sense. This approach utilizes both an odor molecule of the odor of interest and a different odor molecule to thereby inhibit a receptor response to the odor molecule of interest by the different odor molecule, 40 resulting in change in odor which is perceived by individuals. The masking based on olfactory receptor antagonism is distinct from the approach of canceling the odor of interest by a different strong odor of a fragrance or the like, even though these approaches both employ the different odor molecule. 45 One example of the masking based on olfactory receptor antagonism is the case of using a substance, such as an antagonist, which inhibits the response of an olfactory receptor. A substance inhibiting the response of a receptor to an odor molecule responsible for a particular odor can be applied 50 to the receptor to thereby inhibit the response of the receptor to the odor molecule. The odor which is finally perceived by individuals can therefore be changed.

The term "Furaneol" as used herein refers to 2,5-dimethyl-4-hydroxy-3(2H)-furanone. The term "odor caused by Furaneol" can be an odor brought about by 2,5-dimethyl-4-hydroxy-3(2H)-furanone. The "odor caused by Furaneol" or the "odor caused by 2,5-dimethyl-4-hydroxy-3(2H)-furanone" as used herein can be typically expressed as, for example, a caramel aroma or a burnt sugar smell. Also, the "odor caused by Furaneol" or the "odor caused by 2,5-dimethyl-4-hydroxy-3(2H)-furanone" as used herein can be an unpleasant smell generated by the application of a conventional self-tanning agent to the skin, more specifically, an unpleasant smell expressed as a "burnt sugar smell" or the like generated by the application of a skin tanning agent containing dihydroxyacetone (DHA) to the skin.

4

The reported problem of commercially available skin tanning agents (self-tanning agents or sunless tanning agents) is their unique unpleasant smells expressed as earthy, burnt sugar smells, etc. upon application (D. M. Hindenlang and M. E. McDonnell, Cosmetics & Toiletries magazine, 2008, Vol. 123, No. 7, p. 67-74). Thus, improvement in the smells has been demanded. As a result of examining a cause of the unpleasant smell, 2,5-dimethyl-4-hydroxy-3(2H)-furanone (Furaneol) produced via methylglyoxal from dihydroxyacetone (DHA) contained in the skin tanning agents has been found to be a causative substance. For reducing such an unpleasant smell attributed to Furaneol, it has been required to control the odor of Furaneol.

The present inventors searched for an olfactory receptor which responds to Furaneol and successfully identified the receptor. The present inventor has also found that a substance inhibiting the response of the olfactory receptor can inhibit the perception of an odor caused by Furaneol by masking based on olfactory receptor antagonism. On the basis of these findings, the present inventor has found that a substance controlling an odor caused by Furaneol can be searched for with the response of the olfactory receptor as an index.

In the present specification, the sequence identity between nucleotide sequences or amino acid sequences is calculated according to the Lipman-Pearson method (Science, 1985, 227: 1435-41). Specifically, the sequence identity is calculated by analysis using the search homology program (Unit size to compare (ktup): 2) of genetic information processing software Genetyx-Win (Ver. 5.1.1; Software Development Co., Ltd.).

As shown in FIG. 1, the present inventor identified an olfactory receptor OR5K1 as only one receptor responsive to Furaneol from among many olfactory receptors. OR5K1 is a novel receptor for Furaneol which has not been found so far to respond to Furaneol. As shown in FIG. 2, OR5K1 responds to Furaneol in a concentration-dependent manner. Thus, a substance inhibiting the response of OR5K1 can change the perception of an odor caused by Furaneol in the central nervous system by masking based on olfactory receptor antagonism, resulting in the selective inhibition of the odor caused by Furaneol.

According to the present invention, an inhibitor of an odor caused by Furaneol can be efficiently searched for. The inhibitor of an odor caused by Furaneol, identified by the present invention, can selectively deodorize the odor caused by Furaneol by masking based on olfactory receptor antagonism. Thus, the inhibitor of an odor caused by Furaneol, identified by the present invention can deodorize the odor caused by Furaneol, for example, an unpleasant smell generated upon application of conventional self-tanning agents (also called sunless tanning agents), without causing the problems such as discomfort derived from the odor of a fragrance in conventional deodorization methods using a deodorizer or a fragrance.

Thus, the present invention provides a method for searching for an inhibitor of an odor caused by Furaneol. This method comprises: adding a test substance and Furaneol to an olfactory receptor OR5K1; measuring the response of the olfactory receptor to Furaneol; and identifying a test substance inhibiting the response of the olfactory receptor, on the basis of the measured response. The identified test substance is selected as an inhibitor of an odor caused by Furaneol. The method of the present invention can be a method performed in vitro or ex vivo.

In the method of the present invention, a test substance and the odor causative substance Furaneol are added to an olfac-

tory receptor OR5K1. A commercially available product (e.g., FURANEOL®; Nihon Firmenich K.K.) can be purchased and used as Furaneol.

The test substance used in the method of the present invention is not particularly limited as long as the substance is 5 desired to be used as an inhibitor of an odor caused by Furaneol. The test substance may be a naturally occurring substance or may be a substance artificially synthesized by a chemical or biological method or the like. Alternatively, the test substance may be a compound, a composition, or a mix- 10 ture

The olfactory receptor OR5K1 used in the method of the present invention refers to an olfactory receptor expressed on a human olfactory cell and is registered as GI: 115270955 in GenBank. OR5K1 is encoded by a gene having the nucleotide 15 sequence represented by SEQ ID NO: 1. This protein consists of the amino acid sequence represented by SEQ ID NO: 2.

In the method of the present invention, the olfactory receptor OR5K1 can be used in an arbitrary form unless the form loses responsiveness to Furaneol. For example, the olfactory receptor can be used in a form including: tissues or cells naturally expressing the olfactory receptor, such as an osmoreceptor or olfactory cells isolated from an organism, or cultures thereof; the membranes of olfactory cells carrying the olfactory receptor; recombinant cells genetically engineered to express the olfactory receptor, or cultures thereof; the membranes of the recombinant cells having the olfactory receptor; and artificial lipid bilayers having the olfactory receptor. These forms are all included in the scope of the olfactory receptor used in the present invention.

According to a preferred aspect, a cell naturally expressing the olfactory receptor, such as an olfactory cell, or a recombinant cell genetically engineered to express the olfactory receptor, or cultures of any of these cells are used as the olfactory receptor OR5K1. The recombinant cell can be prepared by the transformation of a cell with a vector having an insert of the gene encoding the olfactory receptor.

Preferably, a receptor-transporting protein (RTP) gene, together with the gene of the olfactory receptor, is transferred to the cell in order to promote the expression of the olfactory receptor on the cell membrane. Preferably, an RTP1S gene, more preferably RTP1S and RTP2 genes, together with the gene of the olfactory receptor, are transferred to the cell. Examples of RTP1S and RTP2 include human RTP1S and human RTP1S and human RTP1S in GenBank. This protein is encoded by a gene having the gene sequence represented by SEQ ID NO: 3 and consists of the amino acid sequence represented by SEQ ID NO: 4. The human RTP2 is registered as GI: 258547120 in GenBank. This protein is encoded by a gene having the gene sequence represented by SEQ ID NO: 5 and consists of the amino acid sequence represented by SEQ ID NO: 6.

Alternatively, a polypeptide which consists of an amino acid sequence having at least 78%, for example, 80% or higher, preferably 85% or higher, more preferably 90% or 55 higher, still preferably 95% or higher, even more preferably 98% or higher, still even more preferably 99% or higher sequence identity to the amino acid sequence (SEQ ID NO: 4) of human RTP1S or the amino acid sequence (SEQ ID NO: 6) of human RTP2 and promotes the expression of the olfactory receptor on the cell membrane, as with human RTP1S or RTP2. For example, a human RTP1S variant which is encoded by a gene having the gene sequence represented by SEQ ID NO: 7 and consists of the amino acid sequence represented by SEQ ID NO: 8 has 78.9% sequence identity to the amino acid sequence of human RTP1S represented by SEQ ID NO: 4 and

6

has the function of promoting the expression of the olfactory receptor on the cell membrane. Alternatively, mouse RTP1S (Sci Signal., 2009, 2: ra9) also has 89% sequence identity to the amino acid sequence of human RTP1S represented by SEQ ID NO: 4 and has the function of promoting the expression of the olfactory receptor on the cell membrane. Such a human RTP1S variant and mouse RTP1S can be used instead of the human RTP1S in the preparation of the recombinant cell expressing the olfactory receptor as mentioned above. Alternatively, an RTP1S variant polypeptide which has at least 80%, for example, 80% or higher, preferably 85% or higher, more preferably 90% or higher, still preferably 95% or higher, even more preferably 98% or higher, still even more preferably 99% or higher amino acid sequence identity to the human RTP1S variant consisting of the amino acid sequence represented by SEQ ID NO: 8 or the mouse RTP1S and promotes the expression of the olfactory receptor on the cell membrane may also be used instead of the human RTP1S in the preparation of the recombinant cell expressing the olfactory receptor as mentioned above.

According to the method of the present invention, the response of the olfactory receptor OR5K1 to Furaneol is measured following the addition of the test substance and Furaneol to the olfactory receptor. This measurement can be performed by an arbitrary method known in the art as a method for measuring the response of the olfactory receptor, for example, the measurement of an intracellular cAMP level. For example, the olfactory receptor, when activated by an odor molecule, is known to be conjugated with intracellular Gas to activate adenylate cyclase, thereby increasing intracellular cAMP levels (Mombaerts P. Nat Neurosci. 5, 263-278). Thus, the intracellular cAMP level after the addition of the odor molecule can be used as an index for measuring the response of the olfactory receptor. Examples of methods for measuring the cAMP level include ELISA and reporter gene assay. Another example of the method for measuring the response of the olfactory receptor includes calcium imaging.

Subsequently, the effect of the test substance on the response to Furaneol is evaluated on the basis of the measured response of the olfactory receptor to identify a test substance inhibiting the response. The evaluation on the effect of the test substance can be conducted, for example, by comparing the responses of the receptor to Furaneol measured in the presence of various concentrations of the test substance. As a more specific example, the responses of the receptor to Furaneol are compared between a group supplemented with a higher concentration of the test substance and a group supplemented with a lower concentration of the test substance, between a group supplemented with the test substance and a group non-supplemented with the test substance, between a group supplemented with the test substance and a group supplemented with a control substance, or between before and after the addition of the test substance. When the addition of the test substance or the addition of a higher concentration of the test substance inhibits the response of the receptor, this test substance can be identified as a substance inhibiting the response of the olfactory receptor to Furaneol.

In the method of the present invention, a polypeptide having a function equivalent to OR5K1 can be used as the olfactory receptor instead of OR5K1. Examples of the polypeptide include a polypeptide which consists of an amino acid sequence having at least 80%, for example, 80% or higher, preferably 85% or higher, more preferably 90% or higher, still preferably 95% or higher, even more preferably 98% or higher, still even more preferably 99% or higher sequence identity to the amino acid sequence (SEQ ID NO: 2) of OR5K1 and is responsive to Furaneol.

Alternatively, in the method of the present invention, OR5K1 mentioned above as the olfactory receptor and polypeptides having a function equivalent thereto may each be used alone or may be used in combination of any two or more thereof.

The test substance identified by the above procedures is a substance which can inhibit the individual's perception of an odor caused by Furaneol by inhibiting the response of the olfactory receptor to Furaneol. Thus, the test substance identified by the above procedures is selected as an inhibitor of an 10 odor caused by Furaneol. For example, when the receptor response in a test substance-supplemented group measured by the above procedures is reduced to preferably 60% or less, more preferably 50% or less, further preferably 25% or less of that in a test substance-non-supplemented group (e.g., the 15 above-mentioned group non-supplemented with the test substance, group supplemented with a control substance, or before the addition of the test substance), the test substance can be selected as an inhibitor of an odor caused by Furaneol.

The substance selected by the method of the present inven- 20 tion can inhibit the odor caused by Furaneol, by olfactory masking based on the inhibition of the response of the olfactory receptor to Furaneol.

Thus, in one embodiment, the substance selected by the method of the present invention can serve as an active ingre- 25 dient in an inhibitor of an odor caused by Furaneol. Alternatively, the substance selected by the method of the present invention can be contained as an active ingredient for inhibiting an odor caused by Furaneol in a compound or a composition for inhibiting an odor caused by Furaneol. Alterna- 30 tively, the substance selected by the method of the present invention can be used for production of an inhibitor of an odor caused by Furaneol or for production of a compound or a composition for inhibiting an odor caused by Furaneol.

In one embodiment, the substance selected by the method 35 recombinant cell is the following cell: of the present invention can be used as an active ingredient for inhibiting an odor caused by Furaneol, for example, a caramel aroma, a burnt sugar smell, or an unpleasant smell (e.g., a burnt sugar smell) generated by the application of a selftanning agent to the skin or upon application of a product 40 containing DHA.

In one embodiment, the substance selected by the method of the present invention can be used as an active ingredient for inhibiting an odor caused by Furaneol in every compound or composition desired to inhibit an odor caused by Furaneol or 45 in every environment desired to inhibit an odor caused by Furaneol. Alternatively, the substance selected by the method of the present invention can be used as an active ingredient for inhibiting an odor caused by Furaneol, for production of a compound or a composition desired to inhibit an odor caused 50 by Furaneol. Examples of the compound or the composition desired to inhibit an odor caused by Furaneol include skin tanning agents (also called self-tanning agents or sunless tanning agents), for example, a skin tanning agent containing DHA as a coloring agent and other skin tanning agents which 55 employ browning reaction, and other products containing DHA. Furaneol excessively contained in a food or a drink may work as an off-flavor. For example, the presence of excessive Furaneol in powdered milk reduces its flavor or taste. Thus, other examples of the compound or the composition desired to inhibit an odor caused by Furaneol include foods or drinks desired to reduce the odor of Furaneol and compositions containing the foods or the drinks.

The following composition, production method, use, or method will be further disclosed herein as an exemplary embodiment of the present invention. However, the present invention is not intended to be limited by these embodiments.

<1> A method for searching for an inhibitor of an odor caused by Furaneol, comprising:

adding a test substance and Furaneol to an olfactory receptor OR5K1 or a polypeptide having at least 80% amino acid sequence identity thereto;

measuring the response of the olfactory receptor or the polypeptide to Furaneol; and

identifying a test substance inhibiting the response of the olfactory receptor or the polypeptide, on the basis of the measured response.

<2> The method according to <1>, wherein the olfactory receptor OR5K1 is a protein consisting of the amino acid sequence represented by SEQ ID NO: 2.

<3> The method according to <1> or <2>, wherein the polypeptide having at least 80% amino acid sequence identity to the olfactory receptor OR5K1 is a polypeptide having preferably at least 85%, more preferably at least 90%, still preferably at least 95%, even more preferably at least 98%, still even more preferably at least 99% amino acid sequence identity to the olfactory receptor OR5K1.

<4> The method according to any one of <1> to <3>, wherein the polypeptide having at least 80% amino acid sequence identity to the olfactory receptor OR5K1 is a polypeptide which has preferably at least 85%, more preferably at least 90%, still preferably at least 95%, even more preferably at least 98%, still even more preferably at least 99% amino acid sequence identity to the olfactory receptor OR5K1 and is responsive to Furaneol.

<5> The method according to any one of <1> to <4>, wherein, preferably, the olfactory receptor OR5K1 or the polypeptide having at least 80% amino acid sequence identity thereto is expressed on a recombinant cell genetically engineered to express the olfactory receptor or the polypeptide.

<6>The method according to <5>, wherein, preferably, the

a cell cotransfected with a gene of the olfactory receptor or the polypeptide and an RTP1S gene;

a cell cotransfected with a gene of the olfactory receptor or the polypeptide and RTP1S and RTP2 genes;

a cell cotransfected with a gene of the olfactory receptor or the polypeptide and a gene encoding a polypeptide which consists of an amino acid sequence having at least 78%, preferably 80% or higher, more preferably 85% or higher, still preferably 90% or higher, even more preferably 95% or higher, still even more preferably 98% or higher, further preferably 99% or higher sequence identity to the amino acid sequence represented by SEQ ID NO: 4 and promotes the expression of the olfactory receptor on the membrane, as with human RTP1S; or

a cell cotransfected with a gene of the olfactory receptor or the polypeptide and a gene encoding a human RTP1S variant.

<7> The method according to <5> or <6>, wherein, preferably, cultures of the recombinant cell are used as the olfactory receptor OR5K1 or the polypeptide having at least 80% amino acid sequence identity thereto.

<8> The method according to any one of <1> to <7>, preferably further comprising measuring the response of the olfactory receptor or the polypeptide in the absence of the test substance.

<9> The method according to <8>, preferably further comprising the following:

when the response of the olfactory receptor or the polypeptide in the presence of the test substance is reduced compared with the response of the olfactory receptor or the polypeptide in the absence of the test substance, the test substance is identified as a substance inhibiting the response of the receptor or the polypeptide to Furaneol.

<10> The method according to <8>, preferably further comprising the following:

when the response of the olfactory receptor or the polypeptide in the presence of the test substance is reduced to preferably 60% or less, more preferably 50% or less, further preferably 25% or less, of the response of the olfactory receptor or the polypeptide in the absence of the test substance, the test substance is identified as a substance inhibiting the response of the olfactory receptor or the polypeptide to Furancel

<11> The method according to any one of <1> to <10>, wherein the step of measuring the response of the olfactory receptor or the polypeptide is the measurement of an intracellular cAMP level by ELISA or reporter gene assay, or alcium imaging.

EXAMPLES

Hereinafter, the present invention will be described more $_{\rm 20}$ specifically with reference to Examples.

Example 1

Identification of Olfactory Receptor Responding to Furaneol

1) Cloning of Human Olfactory Receptor Gene

On the basis of sequence information registered in Gen-Bank, each human olfactory receptor gene was cloned by PCR with Human Genomic DNA Female (G1521: Promega Corp.) as a template. Each gene thus amplified by PCR was inserted into a pENTR vector (Invitrogen Corp.) according to the manual. A NotI-AscI site present on the pENTR vector was recombined into a NotI-AScI site prepared downstream of a Flag-Rho tag sequence on a pME18S vector.

2) Preparation of pME18S-Human RTP1S Vector

A human RTP1S gene (SEQ ID NO: 3) encoding human RTP1S (SEQ ID NO: 4) was inserted into the EcoRI-XhoI site of the pME18S vector.

3) Preparation of Olfactory Receptor-Expressing Cell

HEK293 cells expressing each of 400 types of human olfactory receptors were prepared. Each reaction solution having the composition shown in Table 1 was prepared, then left standing for 15 minutes in a clean bench, and then added to each well of a 96-well plate (Becton, Dickinson and Company). Subsequently, the HEK293 cells $(3\times10^5 \text{ cells/cm}^2)$ were inoculated thereto at 100 μ L/well and then cultured at 37° C. for 24 hours in an incubator kept at 5% CO₂.

TABLE 1

OPTI-MEM (GIBCO)	50 μL
Human olfactory receptor gene	0.075 дд
(inserted to N-terminally Flag-	
Rho-tagged pME18S vector)	
pGL4.29 (fluc2P-CRE-hygro,	0.03 μg
Promega)	
pGL4.75 (hRluc-CMV, Promega)	0.03 µg
pME18S-human RTP1S vector	0.03 μg
lipofectamine 2000 (Invitrogen)	0.4 μL

4) Luciferase Assay

The olfactory receptors expressed on the HEK293 cells are conjugated with intracellular $G\alpha s$ to activate adenylate cyclase, thereby increasing intracellular cAMP levels. In this study, their responses to Furaneol were measured using 65 luciferase reporter gene assay which involved monitoring increase in intracellular cAMP level as luminescence inten-

10

sity derived from a firefly luciferase gene (fluc2P-CRE-hygro). In addition, the cells were cotransfected with the reporter gene and a fusion gene (hRluc-CMV) of a *Renilla* luciferase gene downstream of a CMV promoter for use as an internal standard for correcting transfection efficiency or an error in the number of cells.

A medium was removed from the cultures prepared in the preceding paragraph 3). To the resulting cultures, $75~\mu L$ of a solution containing Furaneol (3 mM) prepared with a CD293 medium (Invitrogen Corp.) was added. The cells were cultured for 2.5 hours in a CO $_2$ incubator to express the luciferase genes at sufficient levels in the cells. The luciferase activity was measured using Dual-GloTM luciferase assay system (Promega Corp.) according to the instruction manual of the product. Firefly luciferase-derived luminescence intensity induced by stimulation with Furaneol was divided by luminescence intensity in the cells without Furaneol stimulation to calculate a value as fold increase, which was in turn used as an index for response intensity.

5) Results

40

As a result of measuring the responses of 400 types of olfactory receptors to Furaneol (3 mM), only the olfactory receptor OR5K1 exhibited a response to Furaneol (FIG. 1). OR5K1 is a novel Furaneol receptor which has not been ²⁵ found so far to respond to Furaneol.

Example 2

Concentration-Dependent Response of OR5K1 to Furaneol

The olfactory receptor OR5K1 (SEQ ID NO: 2) was expressed, together with human RTP1S (SEQ ID NO: 4), on HEK293 cells by the same procedures as in Example 1 and then examined for the concentration dependence of its response to varying concentrations of Furaneol (0, 3, 10, 30, 100, 300, 1000, and 3000 µM). As a result, OR5K1 exhibited a concentration-dependent response to Furaneol (FIG. 2).

Example 3

Identification of OR5K1 Antagonist

84 types of test substances were examined for their antago-45 nistic activity against the response of the olfactory receptor OR5K1 to Furaneol.

Furaneol (3 mM) and each test substance (100 μ M) were added to HEK293 cells allowed to express the olfactory receptor OR5K1 by the same procedures as in Example 2. The response of the olfactory receptor was measured to evaluate change in receptor response caused by the addition of the test substance.

The rate of inhibition of the receptor response by the test substance was calculated as follows: firefly luciferase-derived luminescence intensity (Y) in the olfactory receptor OR5K1-expressing cells without Furaneol stimulation was subtracted from firefly luciferase-derived luminescence intensity (X) induced by stimulation with Furaneol alone to determine receptor activity (X-Y) based on the stimulation with Furaneol alone. Likewise, the luminescence intensity (Y) in the cells without Furaneol stimulation was subtracted from luminescence intensity (Z) induced by stimulation with the mixture of Furaneol and the test substance to determine receptor activity (Z-Y) in the presence of the test substance.

The rate of reduction in the receptor activity (Z-Y) in the presence of the test substance with respect to the receptor activity (X-Y) based on the stimulation with Furaneol alone

20

25

11

was calculated according to an expression shown below to determine the rate of inhibition of the receptor response by the test substance. In this assay, a plurality of independent duplicate experiments were performed. An average of the experiments in each run was obtained.

Rate of inhibition (%)= $\{1-(Z-Y)/(X-Y)\}\times 100$

aı

As a result, 17 types of test substances had 40% or higher rate of inhibition of the response of OR5K1 to Furaneol 10 (reduced the response to 60% or less), demonstrating that these test substances have antagonistic activity against OR5K1 (Table 2).

TABLE 2

5% or more rate of	ω-6-Hexadecenlactone (ambrettolide)
nhibition (response	7-Acetyl-1,2,3,4,5,6,7,8-octahydro-1,1,6,7-
vas reduced to 25%	tetramethyl-naphthalene (Iso E Super)
r less; very strong	3-(4-tert-Butylphenyl)propanal (bourgeonal)
ntagonist)	5-Methyl-2-(1-methylethyl)-phenol (thymol)
	$Oxacyclohexadecen-2-one\ (Habanolide(R))$
	(5E)-3-Methylcyclopentadec-5-en-1-one
	(Muscenone(R) Delta)
	Citral
	Patchouli oil
	1-(5,6,7,8-tetrahydro-3,5,5,6,8,8-
	hexamethyl-2-naphthalenyl)-ethanone
	(Tonalid(R))
	4,6,6,7,8,8-Hexamethyl-1,3,4,6,7,8-
	hexahydrocyclopenta[g]isochromene
	(galaxolide)
	(E)-3-Methyl-4-(2,6,6-trimethylcyclohex-2-
	en-1-yl)but-3-en-2-one (methyl ionone-G)
	Muscone
	1-(2,3,4,7,8,8a-hexahydro-3,6,8,8-

12 TABLE 2-continued

	$tetramethyl\hbox{-}1H\hbox{-}3a, 7\hbox{-}methanoazulen\hbox{-}5\hbox{-}yl)\hbox{-}$
	ethanone (acetylcedrene)
50% or more rate of	Cedryl acetate
inhibition	2-Ethyl-4-(2,2,3-trimethyl-3-cyclopenten-1-
(response was	yl)-2-buten-1-ol (bangalol)
reduced to 50% or	
less; strong	
antagonist)	
40% or more rate of	Lemon oil
inhibition	(1-Methyl-2-(1,2,2-trimethylbicyclo[3.1.0]-
(response was	hex-3-ylmethyl)cyclopropyl)methanol
reduced to 60% or	(Javanol(R))
less; weak	
antagonist)	

Example 4

Evaluation on Ability of OR5K1 Antagonist to Inhibit Odor of Furaneol

Each test substance having antagonistic activity against OR5K1, identified in Example 3, was confirmed by a sensory test for its ability to inhibit the odor of Furaneol.

Each panelist smelled 0.5 g of Furaneol (1%)-containing cloth supplemented with 0.5 μL of a flavor, and then evaluated the intensity of the odor of Furaneol compared with cloth non-supplemented with the flavor. The sensory evaluation test was conducted by 3 panelists. The odor of Furaneol was evaluated as 1 when strongly perceivable and as 5 when not perceivable.

As a result, all the 17 types of test substances demonstrated to inhibit the response of OR5K1 to Furaneol in Example 3 inhibited the odor of Furaneol (FIG. 3).

SEQUENCE LISTING

```
<160> NUMBER OF SEQ ID NOS: 8
<210> SEQ ID NO 1
<211> LENGTH: 927
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<223> OTHER INFORMATION: DNA encoding human OR5K1
<400> SEQUENCE: 1
atggctgaag aaaatcatac catgaaaaat gagtttatcc tcacaggatt tacagatcac
                                                                       60
cctgagctga agactctgct gtttgtggtg ttctttgcca tctatctgat caccgtggtg
                                                                      120
gggaatatta gtttggtggc actgatattt acacaccgtc ggcttcacac accaatgtac
                                                                      180
atctttctgg gaaatctggc tcttgtggat tcttgctgtg cctgtgctat tacccccaaa
                                                                      240
atgttagaga acttcttttc tgagaacaaa aggatttccc tctatgaatg tgcagtacag
                                                                      300
ttttattttc tttgcactgt ggaaactgca gactgctttc ttctggcagc aatggcctat
                                                                      360
gaccgctatg tggccatatg caacccactg cagtaccaca tcatgatgtc caagaaactc
```

-continued

tgeattoaga tgaccacagg ggeettoata getegaaace tgeattoat gattoatgta 480 gggettgtat ttaggitagt titetgiggs tegaateace teacacact ttactigts 540 attented gattaagact ctettgit gatectata teaatgaact ggtetatto 600 attented gattaagact ctettgit gatectata teaatgaact ggtetatto 660 attented gattaagact ctettgit gatectata teaatgaact gatectate 660 attented gattaagact agustettace aangaggas gggecaaagt tititetace 720 tgigcatoco actititgic agustaa gataaccag ctecititet caigiacgit 780 agaccacact tgetigaaga aggggataaa gataaccag etgecaatit attiacacta 940 gtagitococt taccaaatca titidattat ageotgagaa atagggaagt aanaaggaa 900 titaagaanaa titigatgaa gaaataa 927		
attottcoct tgtatagact ctottgtgtt gatcottata toaatgaact ggttotatto attottcoag gytoagtton agtotttaco ataggtagtg tottaatato ttatottat attottctta ctattttcaa aatgaaatcc aaagagggas gggccaaagc tttttctacc ttgtgcatccc attitttgc agtttcatta ttetatggat ctcttttett catgtacgtt gagccaaatt tgcttgaaga aggggataaa gatataccag ctgcaattt atttacaata gtagttocot tactaaatcc tttcattat agcctgagaa atagggaagt aataagtgc tttaagaaaaa ttctgatgaa gaaataa 827 **210-SEQ ID NO 2 **210-SEQ ID NO 2 **2113-LENCEN: 388 **212-SEQ ID NO 2 **212-SEQ ID NO 2 **212-SEQ ID NO 2 **212-SEQ ID NO 2 **213-SEQ ID NO 2 **220-FERNITOR: 388 **2210-FERNITOR: 388 **2210-FERNITOR: 388 **2210-FERNITOR: 388 **2210-FERNITOR: 388 **2210-FERNITOR: 388 **2210-FERNITOR: 389	tgcattcaga tgaccacagg ggccttcata gctggaaacc tgcattccat gattcatgta	480
atcttctcag gttcagttca agtcttacc ataggtagtg tcttaatact ttatctctat attottctta ctatttcaa aatgaaatcc aaagagggaa gggocaaagc tttttctacc tgtgcatccc actttttgtc agttcatta ttctatggat ctcttttctt catgtagtt agaccaaatt tgcttgaaga aggggataaa ggataaccag ctgcaattt attacaata gtagttccct tactaaatcc tttcatttat agcctgagaa atagggaagt aataagtgtc ttaagaaaaa ttctgatgaa gaaataa 227	gggcttgtat ttaggttagt tttctgtgga tcgaatcaca tcaaccactt ttactgtgat	540
attotictic ctatiticas aatgasatoc aasgagggas gggccaasgc tittictacc tgtgcatcoc actititgtc agtitoatia titotatggat ctotitict catgtacgtt agaccaaati tgcttgaaga aggggataaa gatataccag ctgcaatit attacaata gtagticcot tactaaatoc titcattat agoctgagaa atagggaagt aataagtgtc ttaagaaaaa titotgatgaa gaaataa 927 **210. SED ID NO 2 **2111. SEDNOTH: 308 **2122 TYPE: PET **213. SEDNOTHS: 308 **2123. TYPE: MFORMATION: Polypeptide of human ORSKI **400. SEQUENCE: 2 Met Ala Glu Glu Amn His Thr Met Lys Amn Glu Phe IIe Leu Thr Gly 15 Phe Thr Asp His Pro Glu Leu Lys Thr Leu Leu Phe Val Val Phe Phe 20 Ala Ile Tyr Leu IIe Thr Val Val Gly Amn IIe Ser Leu Val Ala Leu 35 Ann Leu Ala Leu Val Asp Ser Cys Cys Ala Cys Ala IIe Thr Pro Lys 50 Amn Leu Ala Leu Val Asp Ser Cys Cys Ala Cys Ala IIe Thr Pro Lys 65 Cys Ala Val Gln Phe Tyr Phe Leu Cys Thr Val Glu Thr Ala Asp Cys 110 Phe Leu Leu Ala Ala Met Ala Tyr Asp Arg Tyr Val Ala IIe Cys Asn 115 Pro Leu Gln Tyr His IIe Net Met Ser Lys Lys Lys Leu Cys IIe Gln Met 130 Thr Thr Gly Ala Phe IIe Ala Gly Asn Leu His Fer Met IIe His Val 145 Thr Thr Gly Ala Phe Ile Ala Gly Asn Leu His Fer Met IIe His Val 145 Thr Thr Gly Ala Phe Ile Ala Gly Asn Leu His Fer Met IIe His Val 145 Thr Thr Gly Ala Phe Ile Ala Gly Asn Leu His Fer Met IIe His Val 145 Thr Thr Gly Ala Phe Ile Ala Gly Asn Leu His Fer Met IIe His Val 145 Thr Thr Gly Ala Phe Ile Ala Gly Asn Leu His Fer Met IIe His Val 145 Thr Thr Gly Ala Phe Ile Ala Gly Asn Leu His Fer Met IIe His Val 145 Thr Thr Gly Ala Phe Ile Ala Gly Asn Leu His Fer Met IIe His Val 145 Thr Thr Gly Ala Phe Use Fer Lys Gly Ser Asn His IIe Ann His 150 Gly Leu Val Phe Arg Leu Val Phe Cys Gly Ser Asn His IIe Ann His 165 Thr Thr Gly Ala Phe Use Ser Val Cys Gly Ser Asn His IIe Leu Leu Thr 210 Tyr Ile Asn Glu Leu Val Leu Phe Ile Phe Ser Gly Ser Val Gln Val 210 Tyr Ile Asn Glu Leu Val Leu Phe Ile Phe Ser Gly Ser Val Gln Val 220 The Thr Thr Gly Ser Val Leu IIe Ser Tyr Leu Tyr IIe Leu Leu Thr 221 222 Cys Ala Ser His Phe Leu Ser Val Ser Leu Phe	attetteeet tgtatagaet etettgtgtt gateettata teaatgaaet ggttetatte	600
tgtgcatccc acttitigtc agiticatia tictatggat cictiticti catgiacgit agaccaaati tgcttgaaga aggggataaa gatataccag ctgcaatit attiacaata gtagitccct tactaaatcc titcattat agcctgagaa atagggaagt aataagtgtc 900 ttaagaaaaa tictgatgaa gaaata 927 <210	atottotoag gttoagttoa agtotttaco ataggtagtg tottaatato ttatototat	660
gtagttecct tactaaatc tttcatttat agcctgagaa atagggaagt aataagtgtc ttaagaaaaa ttctgatgaa gaaataa 927 *210 SEO ID NO 2 *211 LENGTH: 308 *212 TYPE: PRT *213 ORGANISM: Homo capiene *220 FEATURE: *2210 SEQUENCE: 2 **Met Ala Glu Glu Aen His Thr Met Lys Aen Glu Phe Ile Leu Thr Gly 1 5 10 10 15 Phe Thr Asp His Thr Val Val Gly Aen Ile Ser Leu Val Ala Leu 35 20 Ala Ile Tyr Leu Ile Thr Val Val Gly Aen Ile Ser Leu Val Ala Leu 35 10 60 Aen Leu Val Aen Phe Ser Glu Aen Hys Ary Ile Phe Leu Cly 50 75 75 80 Met Leu Glu Aen Phe Phe Ser Glu Aen Lys Ary Ile Ser Leu Tyr Glu 96 96 Cys Ala Val Gln Phe Tyr Phe Leu Cys Thr Val Glu Thr Ala Aep Cys 100 Phe Leu Ala Ala Met Ala Tyr Aep Arg Tyr Val Ala Ile Cys Aen 115 Pro Leu Gln Tyr His Ile Met Met Ser Lys Lys Leu Cys Ile Gln Met 130 130 Tyr Ile Aen Glu Leu Val Phe Cys Gly Ser Aen His Ile Aen His 160 175 Phe Tyr Cys Aep Ile Leu Val Phe Ser Gly Ser Aen His Ile Aen His 160 Tyr Tle Aen Glu Leu Val Leu Tyr Arg Leu Ser Cys Val Aep Pro 185 186 187 Phe Tyr Cys Aep Ile Leu Pro Leu Tyr Arg Leu Ser Vys Val Aep Pro 186 187 188 189 Phe Tyr Cys Aep Ile Leu Pro Leu Tyr Arg Leu Ser Vys Val Aep Pro 189 180 180 180 180 180 180 180	attettetta etatttteaa aatgaaatee aaagagggaa gggeeaaage tttttetaee	720
gtagttocct tactamator tttoatttat agortgagaa atagggaagt aataagtgtc ttaagaaaaa ttctgatgaa gaaataa 2210 SEQ ID NO 2 2211 LENCTH: 308 2211 LENCTH: 308 2212 DORGANISM: Nomoo sapiene 2212 PETTURE: 2223 OTHER INFORMATION: Polypeptide of human OR5K1 4400 SEQUENCE: 2 Met Ala Glu Glu Aom His Thr Met Lys Aom Glu Phe Ile Leu Thr Gly 1 5 10 15 Phe Thr Amp His Pro Glu Leu Lys Thr Leu Leu Phe Val Val Phe Phe 20 25 Ala Ile Tyr Leu Ile Thr Val Val Gly Aom Ile Ser Leu Val Ala Leu 35 40 45 Ala Ile Tyr Leu Ile Thr Val Val Gly Aom Ile Ser Leu Val Ala Leu 35 50 Aom Leu Ala Leu Val Amp Ser Cys Cys Ala Cys Ala Ile Thr Pro Lys 65 70 75 80 Met Leu Glu Aom Phe Phe Ser Glu Aom Lys Arg Ile Ser Leu Tyr Glu 85 95 Cys Ala Val Gln Phe Tyr Phe Leu Cys Thr Val Glu Thr Ala Amp Cys 105 Phe Leu La Ala Ala Met Ala Tyr Amp Arg Tyr Val Ala Ile Cys Amn 115 120 Thr Thr Gly Ala Phe Ile Ala Gly Aom Leu His Ser Met Ile His Val 145 150 Thr Thr Gly Ala Phe Ile Ala Gly Aom Leu His Ser Met Ile His Val 146 177 Phe Tyr Cys Amp Ile Leu Pro Leu Tyr Arg Leu Ser Cys Val Amp Pro 180 Tyr Ile Aom Glu Leu Val Leu Phe Ile Phe Ser Gly Ser Val Ala Phe Pro 180 Tyr Ile Aom Glu Leu Val Leu Phe Ile Phe Ser Gly Ser Val Gln Val 195 205 Phe Thr Ile Gly Ser Val Leu Ile Ser Tyr Leu Tyr Ile Leu Leu Thr 210 215 220 Ile Phe Lys Met Lys Ser Lys Glu Gly Arg Ala Lys Ala Phe Ser Thr 225 230 Cys Ala Ser His Phe Leu Ser Val Ser Leu Phe Tyr Gly Ser Leu Phe 245 250 Phe Met Tyr Val Arg Pro Aom Leu Leu Glu Glu Gly Amp Lys Amp Ile	tgtgcatccc actttttgtc agtttcatta ttctatggat ctcttttctt catgtacgtt	780
**Clos SEQ ID NO 2 **Clos SEQ ID NO 2 **Clos SEQ ID NO 2 **Clos SEQUENCE: 2 **Sequence of the sequence of the	agaccaaatt tgcttgaaga aggggataaa gatataccag ctgcaatttt atttacaata	840
<pre><210 > SEQ ID NO 2 <211 > LENGTH: 308 </pre> <pre><2121 > LENGTH: 308 </pre> <pre><2123 > OREAINS: Nome sapiens <pre><2223 > OTHER INFORMATION: Polypeptide of human OREKI </pre> <pre><400 > SEQUENCE: 2</pre> <pre>Met Ala Glu Glu Asn His Thr Met Lys Asn Glu Phe Ile Leu Thr Gly 1</pre></pre>	gtagttccct tactaaatcc tttcatttat agcctgagaa atagggaagt aataagtgtc	900
2212> TVEP: PRT 2213> ORGANISM: Homo sapiens 2203> FRATURE: 2203> CARRI INFORMATION: Folypeptide of human ORSKI 2400> SEQUENCE: 2 Met Ala Glu Glu Ason His Thr Met Lys Ason Glu Phe IIe Leu Thr Gly 1	ttaagaaaaa ttctgatgaa gaaataa	927
Met Ala Glu Glu Asn His Thr Met Lys Asn Glu Phe Ile Leu Thr Gly 1	<211> LENGTH: 308 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <220> FEATURE:	
1	<400> SEQUENCE: 2	
Ala Ile Tyr Leu Ile Thr Val Val Gly Asn Ile Ser Leu Val Ala Leu 45 Ile Phe Thr His Arg Arg Leu His Thr Pro Met Tyr Ile Phe Leu Gly 50 Asn Leu Ala Leu Val Asp Ser Cys Cys Ala Cys Ala Ile Thr Pro Lys 65 Asn Leu Ala Leu Val Asp Ser Cys Cys Ala Cys Ala Ile Thr Pro Lys 65 Net Leu Glu Asn Phe Phe Ser Glu Asn Lys Arg Ile Ser Leu Tyr Glu 90 Cys Ala Val Gln Phe Tyr Phe Leu Cys Thr Val Glu Thr Ala Asp Cys 110 Phe Leu Leu Ala Ala Met Ala Tyr Asp Arg Tyr Val Ala Ile Cys Asn 115 Pro Leu Gln Tyr His Ile Met Met Ser Lys Lys Leu Cys Ile Gln Met 130 Thr Thr Gly Ala Phe Ile Ala Gly Asn Leu His Ser Met Ile His Val 145 Gly Leu Val Phe Arg Leu Val Phe Cys Gly Ser Asn His Ile Asn His 165 Tyr Ile Asn Glu Leu Val Leu Phe Ile Phe Ser Gly Ser Val Gln Val 195 Phe Thr Ile Gly Ser Val Leu Ile Ser Tyr Leu Tyr Ile Leu Leu Thr 210 Phe Lys Met Lys Ser Lys Glu Gly Arg Ala Phe Ser Thr 225 Phe Met Tyr Val Arg Pro Asn Leu Leu Glu Glu Gly Asp Lys Asp Ile		
11c Phe Thr His Arg Arg Leu His Thr Pro Met Tyr Ile Phe Leu Gly 55 Asn Leu Ala Leu Val Asp Ser Cys Cys Ala Cys Ala Ile Thr Pro Lys 65 Asn Leu Ala Leu Val Asp Ser Cys Cys Ala Cys Ala Ile Thr Pro Lys 65 Met Leu Glu Asn Phe Phe Ser Glu Asn Lys Arg Ile Ser Leu Tyr Glu 85 Cys Ala Val Gln Phe Tyr Phe Leu Cys Thr Val Glu Thr Ala Asp Cys 100 Phe Leu Leu Ala Ala Met Ala Tyr Asp Arg Tyr Val Ala Ile Cys Asn 115 Pro Leu Gln Tyr His Ile Met Met Ser Lys Lys Leu Cys Ile Gln Met 130 Thr Thr Gly Ala Phe Ile Ala Gly Asn Leu His Ser Met Ile His Val 145 Gly Leu Val Phe Arg Leu Val Phe Cys Gly Ser Asn His Ile Asn His 166 Gly Leu Val Phe Arg Leu Pro Leu Tyr Arg Leu Ser Cys Val Asp Pro 180 Tyr Ile Asn Glu Leu Val Leu Phe Ile Phe Ser Gly Ser Val Gln Val 205 Phe Thr Ile Gly Ser Val Leu Ile Ser Tyr Leu Tyr Ile Leu Leu Thr 210 Leu Ser Lys Glu Gly Arg Ala Lys Ala Phe Ser Thr 225 Phe Met Tyr Val Asg Pro Asn Leu Leu Glu Glu Gly Asp Lys Asp Ile Met Tyr Val Arg Pro Asn Leu Leu Glu Gly Asp Lys Asp Ile		
Asn Leu Ala Leu Val Asp Ser Cys Cys Ala Cys Ala Ile Thr Pro Lys 80 Met Leu Glu Asn Phe Pe Ser Glu Asn Lys Arg Ile Ser Leu Tyr Glu 95 Cys Ala Val Gln Phe Tyr Phe Leu Cys Thr Val Glu Thr Ala Asp Cys 100 Phe Leu Leu Ala Ala Met Ala Tyr Asp Arg Tyr Val Ala Ile Cys Asn 115 Pro Leu Gln Tyr His Ile Met Met Ser Lys Lys Leu Cys Ile Gln Met 130 Thr Thr Gly Ala Phe Ile Ala Gly Asn Leu His Ser Met Ile His Val 145 Gly Leu Val Phe Arg Leu Val Phe Cys Gly Ser Asn His Ile Asn His 175 Phe Tyr Cys Asp Ile Leu Pro Leu Tyr Arg Leu Ser Cys Val Asp Pro 180 Tyr Ile Asn Glu Leu Val Leu Phe Ile Phe Ser Gly Ser Val Gln Val 195 Phe Thr Ile Gly Ser Val Leu Ile Ser Tyr Leu Tyr Ile Leu Leu Thr 210 The Phe Lys Met Lys Ser Lys Glu Gly Arg Ala Lys Ala Phe Ser Thr 240 Cys Ala Ser His Phe Leu Ser Val Ser Leu Phe Tyr Gly Ser Leu Phe 255 Phe Met Tyr Val Arg Pro Asn Leu Leu Glu Glu Gly Asp Lys Asp Ile		
Met Leu Glu Asn Phe Phe Ser Glu Asn Lys Arg Ile Ser Leu Tyr Glu 95 Cys Ala Val Gln Phe Tyr Phe Leu Cys Thr Val Glu Thr Ala Asp Cys 1100 Phe Leu Leu Ala Ala Met Ala Tyr Asp Arg Tyr Val Ala Ile Cys Asn 115 Pro Leu Gln Tyr His Ile Met Met Ser Lys Lys Leu Cys Ile Gln Met 130 Thr Thr Gly Ala Phe Ile Ala Gly Asn Leu His Ser Met Ile His Val 145 Gly Leu Val Phe Arg Leu Val Phe Cys Gly Ser Asn His Ile Asn His 170 Phe Tyr Cys Asp Ile Leu Pro Leu Tyr Arg Leu Ser Cys Val Asp Pro 180 Tyr Ile Asn Glu Leu Val Leu Phe Ile Phe Ser Gly Ser Val Gln Val 205 Phe Thr Ile Gly Ser Val Leu Ile Ser Tyr Leu Tyr Ile Leu Leu Thr 210 Ile Phe Lys Met Lys Ser Lys Glu Gly Arg Ala Lys Ala Phe Ser Thr 230 Cys Ala Ser His Phe Leu Ser Val Ser Leu Phe Tyr Gly Ser Leu Phe 255 Phe Met Tyr Val Arg Pro Asn Leu Leu Glu Glu Gly Asp Lys Asp Ile		
Cys Ala Val Gln Phe Tyr Phe Leu Cys Thr Val Glu Thr Ala Asp Cys 1100 Phe Leu Leu Ala Ala Met Ala Tyr Asp Arg Tyr Val Ala Ile Cys Asn 115 Pro Leu Gln Tyr His Ile Met Met Ser Lys Lys Leu Cys Ile Gln Met 130 Thr Thr Gly Ala Phe Ile Ala Gly Asn Leu His Ser Met Ile His Val 145 Gly Leu Val Phe Arg Leu Val Phe Cys Gly Ser Asn His Ile Asn His 175 Phe Tyr Cys Asp Ile Leu Pro Leu Tyr Arg Leu Ser Cys Val Asp Pro 180 Tyr Ile Asn Glu Leu Val Leu Phe Ile Phe Ser Gly Ser Val Gln Val 205 Phe Thr Ile Gly Ser Val Leu Ile Ser Tyr Leu Tyr Ile Leu Leu Thr 210 Ile Phe Lys Met Lys Ser Lys Glu Gly Arg Ala Lys Ala Phe Ser Thr 240 Cys Ala Ser His Phe Leu Ser Val Ser Leu Phe Tyr Gly Ser Leu Phe 255 Phe Met Tyr Val Arg Pro Asn Leu Leu Glu Glu Gly Asp Lys Asp Ile		
Phe Leu Leu Ala Ala Met Ala Tyr Asp Arg Tyr Val Ala Ile Cys Asn 115 Pro Leu Gln Tyr His Ile Met Met Ser Lys Lys Leu Cys Ile Gln Met 130 Thr Thr Gly Ala Phe Ile Ala Gly Asn Leu His Ser Met Ile His Val 145 Gly Leu Val Phe Arg Leu Val Phe Cys Gly Ser Asn His Ile Asn His 165 Phe Tyr Cys Asp Ile Leu Pro Leu Tyr Arg Leu Ser Cys Val Asp Pro 180 Tyr Ile Asn Glu Leu Val Leu Phe Ile Phe Ser Gly Ser Val Gln Val 195 Phe Thr Ile Gly Ser Val Leu Ile Ser Tyr Leu Tyr Ile Leu Leu Thr 210 Phe Lys Met Lys Ser Lys Glu Gly Arg Ala Lys Ala Phe Ser Thr 225 Phe Met Tyr Val Arg Pro Asn Leu Leu Glu Glu Gly Asp Lys Asp Ile		
Pro Leu Gln Tyr His Ile Met Met Ser Lys Lys Leu Cys Ile Gln Met		
Thr Thr Gly Ala Phe Ile Ala Gly Asn Leu His Ser Met Ile His Val 155 Gly Leu Val Phe Arg Leu Val Phe Cys Gly Ser Asn His Ile Asn His 175 Phe Tyr Cys Asp Ile Leu Pro Leu Tyr Arg Leu Ser Cys Val Asp Pro 180 Tyr Ile Asn Glu Leu Val Leu Phe Ile Phe Ser Gly Ser Val Gln Val 205 Phe Thr Ile Gly Ser Val Leu Ile Ser Tyr Leu Tyr Ile Leu Eu Thr 210 Ile Phe Lys Met Lys Ser Lys Glu Gly Arg Ala Lys Ala Phe Ser Thr 225 Cys Ala Ser His Phe Leu Ser Val Ser Leu Phe Tyr Gly Ser Leu Phe 255 Phe Met Tyr Val Arg Pro Asn Leu Leu Glu Glu Gly Asp Lys Asp Ile		
Gly Leu Val Phe Arg Leu Val Phe Cys Gly Ser Asn His Ile Asn His 175 Phe Tyr Cys Asp Ile Leu Pro Leu Tyr Arg Leu Ser Cys Val Asp Pro 180 Tyr Ile Asn Glu Leu Val Leu Phe Ile Phe Ser Gly Ser Val Gln Val 205 Phe Thr Ile Gly Ser Val Leu Ile Ser Tyr Leu Tyr Ile Leu Leu Thr 210 Ile Phe Lys Met Lys Ser Lys Glu Gly Arg Ala Lys Ala Phe Ser Thr 225 Cys Ala Ser His Phe Leu Ser Val Ser Leu Phe Tyr Gly Ser Leu Phe 255 Phe Met Tyr Val Arg Pro Asn Leu Leu Glu Glu Gly Asp Lys Asp Ile		
Phe Tyr Cys Asp Ile Leu Pro Leu Tyr Arg Leu Ser Cys Val Asp Pro 180 Tyr Ile Asn Glu Leu Val Leu Phe Ile Phe Ser Gly Ser Val Gln Val 195 Phe Thr Ile Gly Ser Val Leu Ile Ser Tyr Leu Tyr Ile Leu Eu Thr 210 Tle Phe Lys Met Lys Ser Lys Glu Gly Arg Ala Lys Ala Phe Ser Thr 225 Cys Ala Ser His Phe Leu Ser Val Ser Leu Phe Tyr Gly Ser Leu Phe 245 Phe Met Tyr Val Arg Pro Asn Leu Leu Glu Glu Gly Asp Lys Asp Ile		
Tyr Ile Asn Glu Leu Val Leu Phe Ile Phe Ser Gly Ser Val Gln Val 195 Phe Thr Ile Gly Ser Val Leu Ile Ser Tyr Leu Tyr Ile Leu Leu Thr 210 Ile Phe Lys Met Lys Ser Lys Glu Gly Arg Ala Lys Ala Phe Ser Thr 225 Cys Ala Ser His Phe Leu Ser Val Ser Leu Phe Tyr Gly Ser Leu Phe 245 Phe Met Tyr Val Arg Pro Asn Leu Leu Glu Glu Gly Asp Lys Asp Ile		
Phe Thr Ile Gly Ser Val Leu Ile Ser Tyr Leu Tyr Ile Leu Leu Thr 210 Tle Phe Lys Met Lys Ser Lys Glu Gly Arg Ala Lys Ala Phe Ser Thr 225 Cys Ala Ser His Phe Leu Ser Val Ser Leu Phe Tyr Gly Ser Leu Phe 245 Phe Met Tyr Val Arg Pro Asn Leu Leu Glu Glu Gly Asp Lys Asp Ile		
210 215 220 Ille Phe Lys Met Lys Ser Lys Glu Gly Arg Ala Lys Ala Phe Ser Thr 225 Cys Ala Ser His Phe Leu Ser Val Ser Leu Phe Tyr Gly Ser Leu Phe 245 Phe Met Tyr Val Arg Pro Asn Leu Leu Glu Glu Gly Asp Lys Asp Ile		
225 230 235 240 Cys Ala Ser His Phe Leu Ser Val Ser Leu Phe Tyr Gly Ser Leu Phe 245 250 255 Phe Met Tyr Val Arg Pro Asn Leu Leu Glu Glu Gly Asp Lys Asp Ile		
245 250 255 Phe Met Tyr Val Arg Pro Asn Leu Leu Glu Glu Gly Asp Lys Asp Ile		

-continued

Pro Ala Ala Ile Leu Phe Thr Ile Val Val Pro Leu Leu Asn Pro Phe 275 280 Ile Tyr Ser Leu Arg Asn Arg Glu Val Ile Ser Val Leu Arg Lys Ile 295 Leu Met Lys Lys 305 <210> SEQ ID NO 3 <211> LENGTH: 684 <212> TYPE: DNA <213 > ORGANISM: Homo sapiens <223> OTHER INFORMATION: DNA encoding human RTP1S <400> SEQUENCE: 3 atgtgtaaaa gcgtgaccac agatgagtgg aagaaagtct tctatgagaa gatggaggag 60 120 gcaaagccgg ctgacagctg ggacctcatc atagacccca acctcaagca caatgtgctg agccctggtt ggaagcagta cctggaattg catgcttcag gcaggttcca ctgctcctgg 180 tgctggcaca cctggcagtc gccctacgtg gtcatcctct tccacatgtt cctggaccgc 240 gcccagcggg cgggctcggt gcgcatgcgc gtcttcaagc agctgtgcta tgagtgcggc 300 acqqcqcqqc tqqacqaqtc caqcatqctq qaqqaqaaca tcqaqqqcct qqtqqacaac 360 ctcatcacca gcctgcqcqa qcaqtqctac qgcqaqcqtq qcqqccaqta ccqcatccac 420 480 gtggccagcc gccaggacaa ccggcggcac cgcggagagt tctgcgaggc ctgccaggag ggcatcgtgc actggaagcc cagcgagaag ctgctggagg aggaggcgac cacctacacc 540 tteteeeggg egeeeageee caceaagteg eaggaceaga egggeteagg etggaaette 600 tgctctatcc cctggtgctt gttttgggcc acggtcctgc tgctgatcat ctacctgcag 660 ttctctttcc gtagctccgt ataa 684 <210> SEQ ID NO 4 <211> LENGTH: 227 <212> TYPE: PRT <213 > ORGANISM: Homo sapiens <220> FEATURE: <223> OTHER INFORMATION: Polypeptide of human RTP1S <400> SEQUENCE: 4 Met Cys Lys Ser Val Thr Thr Asp Glu Trp Lys Lys Val Phe Tyr Glu Lys Met Glu Glu Ala Lys Pro Ala Asp Ser Trp Asp Leu Ile Ile Asp Pro Asn Leu Lys His Asn Val Leu Ser Pro Gly Trp Lys Gln Tyr Leu Glu Leu His Ala Ser Gly Arg Phe His Cys Ser Trp Cys Trp His Thr Trp Gln Ser Pro Tyr Val Val Ile Leu Phe His Met Phe Leu Asp Arg Ala Gln Arg Ala Gly Ser Val Arg Met Arg Val Phe Lys Gln Leu Cys Tyr Glu Cys Gly Thr Ala Arg Leu Asp Glu Ser Ser Met Leu Glu Glu 105 Asn Ile Glu Gly Leu Val Asp Asn Leu Ile Thr Ser Leu Arg Glu Gln 120 125 Cys Tyr Gly Glu Arg Gly Gly Gln Tyr Arg Ile His Val Ala Ser Arg 130 135 140

-continued

Gln Asp Asn Arg Arg His Arg Gly Glu Phe Cys Glu Ala Cys Gln Glu 150 Gly Ile Val His Trp Lys Pro Ser Glu Lys Leu Leu Glu Glu Glu Ala Thr Thr Tyr Thr Phe Ser Arg Ala Pro Ser Pro Thr Lys Ser Gln Asp Gln Thr Gly Ser Gly Trp Asn Phe Cys Ser Ile Pro Trp Cys Leu Phe 200 Trp Ala Thr Val Leu Leu Ile Ile Tyr Leu Gln Phe Ser Phe Arg Ser Ser Val 225 <210> SEQ ID NO 5 <211> LENGTH: 678 <212> TYPE: DNA <213 > ORGANISM: Homo sapiens <220> FEATURE: <223> OTHER INFORMATION: DNA encoding human RTP2 <400> SEQUENCE: 5 atqtqtacca qcttqaccac ttqtqaqtqq aaqaaaqtct tctatqaqaa qatqqaqqtq 60 gcaaagccag cggacagctg ggagctcatc atagacccca acctcaagcc cagtgagctg 120 qcccctqqct qqaaqcaqta cctqqaqcaq cacqcctcaq qcaqqttcca ctqctcctqq 180 tgctggcaca cctggcagtc tgcccatgtg gtcatcctct tccacatgtt cctggaccgc 240 geecageggg egggeteggt gegeatgege gtetteaage agetgtgeta tgagtgegge 300 acggcgcggc tggacgagtc cagcatgctg gaggagaaca tcgagggcct ggtggacaac 360 ctcatcacca gcctgcgcga gcagtgctac gaggaggatg gtggccagta ccgcatccac 420 gtggccagcc gcccggacag cgggccgcat cgtgcagagt tctgtgaggc ctgccaggag 480 ggcatcgttc actggaagcc cagcgagaag ctgctggagg aggaggtgac cacctacacc 540 totgaagoot ocaagoogag ggoocaggog ggatooggot acaacttott gtotottogo 600 tggtgcctct tctgggcctc tctctgcctg ctcgttgttt acctgcagtt ctccttcctc 660 agtcctgcct tcttttag 678 <210> SEQ ID NO 6 <211> LENGTH: 225 <212> TYPE: PRT <213 > ORGANISM: Homo sapiens <220> FEATURE: <223> OTHER INFORMATION: Polypeptide of human RTP2 <400> SEQUENCE: 6 Met Cys Thr Ser Leu Thr Thr Cys Glu Trp Lys Lys Val Phe Tyr Glu Lys Met Glu Val Ala Lys Pro Ala Asp Ser Trp Glu Leu Ile Ile Asp 25 Pro Asn Leu Lys Pro Ser Glu Leu Ala Pro Gly Trp Lys Gln Tyr Leu Glu Gln His Ala Ser Gly Arg Phe His Cys Ser Trp Cys Trp His Thr Trp Gln Ser Ala His Val Val Ile Leu Phe His Met Phe Leu Asp Arg 75 Ala Gln Arg Ala Gly Ser Val Arg Met Arg Val Phe Lys Gln Leu Cys

-continued

90 Tyr Glu Cys Gly Thr Ala Arg Leu Asp Glu Ser Ser Met Leu Glu Glu 100 105 110 Asn Ile Glu Gly Leu Val Asp Asn Leu Ile Thr Ser Leu Arg Glu Gln 120 Cys Tyr Glu Glu Asp Gly Gly Gln Tyr Arg Ile His Val Ala Ser Arg 135 Pro Asp Ser Gly Pro His Arg Ala Glu Phe Cys Glu Ala Cys Gln Glu Gly Ile Val His Trp Lys Pro Ser Glu Lys Leu Leu Glu Glu Glu Val Thr Thr Tyr Thr Ser Glu Ala Ser Lys Pro Arg Ala Gln Ala Gly Ser Gly Tyr Asn Phe Leu Ser Leu Arg Trp Cys Leu Phe Trp Ala Ser Leu Cys Leu Leu Val Val Tyr Leu Gln Phe Ser Phe Leu Ser Pro Ala Phe 215 Phe 225 <210> SEO ID NO 7 <211> LENGTH: 681 <212> TYPE: DNA <213 > ORGANISM: Homo sapiens <220> FEATURE: <223> OTHER INFORMATION: DNA encoding polypeptide of recombinant human RTP1S <400> SEQUENCE: 7 atgtgcaagt ccctgacaac gggagagtgg aagaagatct tctacgagaa aatggaggag 60 gtgaaacccg cagactcctg ggacctgatc atggatccca acctccagca taacgtattg 120 gcccccggat ggaagcagta cctggagcag cacgcctctg gccgcttcca ctgctcctgg 180 tgctggcata gctggcagtc ctcccaactg gtgatcctct tccacatgta cctggataag 240 acccagegga egggetgegt gegeatgaga gtetteaage agetetgeta egagtgtgge 300 tectecegge tggacgagte gtecatgetg gaggagaaca tagagggget ggtggacaac ctcgtctgca gcctccggga gcagtgctac ggggagaatg ggggacagta ccgcatccac gtggcctccc gccaagacca ccagcgccac cggggagagt tctgcgaggc ctgccgcctg ggcatcaccc actggaagcc cacggagaag atgctagagg aggaggcctc cacctacacc ttctcccggc ctgcgaatcc ttccaagaca gccgactcgg gtttcagctg tgacttctgc tecetecett ggtgtatgtt etgggeeaeg gtgetettge teateatata eetgeagate teetteggea accetgteta a 681 <210> SEQ ID NO 8 <211> LENGTH: 226 <212> TYPE: PRT <213 > ORGANISM: Homo sapiens <220> FEATURE: <223> OTHER INFORMATION: Polypeptide of recombinant human RTP1S <400> SEQUENCE: 8 Met Cys Lys Ser Leu Thr Thr Gly Glu Trp Lys Lys Ile Phe Tyr Glu 10

Lys Met Glu Glu Val Lys Pro Ala Asp Ser Trp Asp Leu Ile Met Asp $20 \hspace{1.5cm} 25 \hspace{1.5cm} 30$

-continued

Pro	Asn	Leu 35	Gln	His	Asn	Val	Leu 40	Ala	Pro	Gly	Trp	Lys 45	Gln	Tyr	Leu
Glu	Gln 50	His	Ala	Ser	Gly	Arg 55	Phe	His	Сув	Ser	Trp 60	Cys	Trp	His	Ser
Trp 65	Gln	Ser	Ser	Gln	Leu 70	Val	Ile	Leu	Phe	His 75	Met	Tyr	Leu	Asp	80 Fåa
Thr	Gln	Arg	Thr	Gly 85	CAa	Val	Arg	Met	Arg 90	Val	Phe	ГÀа	Gln	Leu 95	Cys
Tyr	Glu	СЛа	Gly 100	Ser	Ser	Arg	Leu	Asp 105	Glu	Ser	Ser	Met	Leu 110	Glu	Glu
Asn	Ile	Glu 115	Gly	Leu	Val	Asp	Asn 120	Leu	Val	CÀa	Ser	Leu 125	Arg	Glu	Gln
Cys	Tyr 130	Gly	Glu	Asn	Gly	Gly 135	Gln	Tyr	Arg	Ile	His 140	Val	Ala	Ser	Arg
Gln 145	Asp	His	Gln	Arg	His 150	Arg	Gly	Glu	Phe	Сув 155	Glu	Ala	Cys	Arg	Leu 160
Gly	Ile	Thr	His	Trp 165	Lys	Pro	Thr	Glu	Lys 170	Met	Leu	Glu	Glu	Glu 175	Ala
Ser	Thr	Tyr	Thr 180	Phe	Ser	Arg	Pro	Ala 185	Asn	Pro	Ser	Lys	Thr 190	Ala	Asp
Ser	Gly	Phe 195	Ser	Cys	Asp	Phe	Cys 200	Ser	Leu	Pro	Trp	Cys 205	Met	Phe	Trp
Ala	Thr 210	Val	Leu	Leu	Leu	Ile 215	Ile	Tyr	Leu	Gln	Ile 220	Ser	Phe	Gly	Asn
Pro 225	Val														

The invention claimed is:

- 1. A method of screening for an inhibitor of an odor caused by 2,5-dimethyl-4-hydroxy-3(2H)-furanone, comprising:
 - (1), adding a test substance and 2,5-dimethyl-4-hydroxy-3(2H)-furanone to a cultured cell expressing olfactory receptor OR5K1, wherein the amino acid sequence of olfactory receptor OR5K1 consists of the amino acid sequence of SEQ ID NO:2, or a polypeptide having at least 95% amino acid sequence identity thereto;

 45
 - (2) measuring the response of the olfactory receptor or the polypeptide to 2,5-dimethyl-4-hydroxy-3(2H)-furanone; and
 - (3) identifying a test substance that inhibits the response measured in (2) as an inhibitor of the odor.
- 2. The method according to claim 1, wherein the cultured cell expresses olfactory receptor OR5K1 that has an amino acid sequence that consists of the amino acid sequence of SEQ ID NO: 2.
- 3. The method according to claim 1, wherein the polypeptide having at least 95% amino acid sequence identity to the olfactory receptor OR5K1 is a polypeptide which consists of an amino acid sequence having at least 95% identity to the amino acid sequence represented by SEQ ID NO: 2 and is responsive to 2,5-dimethyl-4-hydroxy-3(2H)-furanone.
- 4. The method according to claim 1, wherein the olfactory receptor OR5K1 or the polypeptide having at least 95% amino acid sequence identity thereto is expressed on a recombinant cell genetically engineered to express the olfactory receptor or the polypeptide.

- **5**. The method according to claim **1**, further comprising measuring the response of the olfactory receptor or the polypeptide in the absence of the test substance.
- **6**. The method according to claim **5**, wherein when the response of the olfactory receptor or the polypeptide in the presence of the test substance is reduced to 60% or less of the response of the olfactory receptor or the polypeptide in the absence of the test substance, the test substance is identified as a substance inhibiting the response of the olfactory receptor or the polypeptide to 2,5-dimethyl-4-hydroxy-3(2H)-furanone.
- 7. The method according to claim 1, wherein the step of measuring the response of the olfactory receptor or the polypeptide is the measurement of an intracellular cAMP level by ELISA or reporter gene assay, or calcium imaging.
- 8. The method according to claim 1, wherein the cultured cell expressing the olfactory receptor OR5K1 or the polypeptide having at least 95% amino acid sequence identity thereto is a recombinant cell genetically engineered to express the olfactory receptor or the polypeptide.
- 9. The method according to claim 1, wherein the cultured cell expresses a polypeptide having at least 95% amino acid sequence identity to the olfactory receptor OR5K1.
- 10. The method according to claim 9, wherein the polypeptide has at least 98% amino acid sequence identity to olfactory receptor OR5K1.
- 11. The method according to claim 10, wherein the polypeptide has at least 99% amino acid sequence identity to olfactory receptor OR5K1.

* * * * *